Genpharm is pleased to announce joining MassBio. Allowing us to further assist the Life Science ecosystem, not just in Cambridge, but on both national and international levels. As a commercial pharmaceutical partner for the Middle East region focused on providing access to rare and genetic disease therapies, Genpharm is committed to working with current MassBio members interested in expanding across the Middle East and North Africa region.
Being that Genpharm is the only company to have successfully introduced gene and cell therapies to the region, we’re uniquely positioned to work with MassBio and service an unmet need within the rare disease sector. In addition to commercial launches, one of Genpharms main focuses, is to support companies that are looking to enroll patients in their global clinical trials. We work closely with all the regional scientific societies and key stakeholders such as regulators and payors. Our core activities evolve around disease awareness, patient diagnosis, and access to therapy.
Our current partners are Novartis GT, Orchard, PTC, Sarepta, Argenx, Albireo, Amicus, Ultragenyx, Quoin and others.
Learn more about Genpharm here:
- Genpharm Company Profile https://bit.ly/3qx8664
- White Paper on the MENA Rare Disease Landscape https://bit.ly/3RDCpUp
- Rare Revolution Magazine GCC Geographical Spotlight http://bit.ly/RDD-MENA-GCC